Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Shares Issued (2018 - 2025)

Historic Shares Issued for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $9.7 million.

  • Neurogene's Shares Issued rose 669230.77% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.2 million, marking a year-over-year increase of 11229.18%. This contributed to the annual value of $189.6 million for FY2024, which is 10530.96% up from last year.
  • Per Neurogene's latest filing, its Shares Issued stood at $9.7 million for Q3 2025, which was up 669230.77% from $68000.0 recorded in Q2 2025.
  • In the past 5 years, Neurogene's Shares Issued registered a high of $188.4 million during Q4 2024, and its lowest value of $19000.0 during Q1 2025.
  • For the 3-year period, Neurogene's Shares Issued averaged around $26.5 million, with its median value being $143000.0 (2024).
  • Within the past 5 years, the most significant YoY rise in Neurogene's Shares Issued was 669230.77% (2025), while the steepest drop was 9697.93% (2025).
  • Quarter analysis of 3 years shows Neurogene's Shares Issued stood at $92.2 million in 2023, then soared by 104.39% to $188.4 million in 2024, then plummeted by 94.84% to $9.7 million in 2025.
  • Its last three reported values are $9.7 million in Q3 2025, $68000.0 for Q2 2025, and $19000.0 during Q1 2025.